Maxygen, (FRA:MYN) Total Current Assets : €62.85 Mil (As of Mar. 2013)

View and export this data going back to . Start your Free Trial

What is Maxygen, Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Maxygen,'s total current assets for the quarter that ended in Mar. 2013 was €62.85 Mil.

Maxygen, Total Current Assets Historical Data

The historical data trend for Maxygen,'s Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maxygen, Total Current Assets Chart

Maxygen, Annual Data

Trend

Dec03

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Total Current Assets

Get a 7-Day Free Trial

156.30

120.37

107.29

124.92

63.33

Maxygen, Quarterly Data
	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13
Total Current Assets	Get a 7-Day Free Trial															120.50	148.66	66.43	63.33	62.85

Maxygen, Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Maxygen,'s Total Current Assets for the fiscal year that ended in Dec. 2012 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	63.136	+	0	+	0	+	0.192
	=	63.33

Maxygen,'s Total Current Assets for the quarter that ended in Mar. 2013 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	62.637	+	0	+	0	+	0.215
	=	62.85

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Maxygen, (FRA:MYN) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Maxygen,'s Liquidation Value for the quarter that ended in Mar. 2013 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	62.637	-	2.253	+	0.75 * 0	+	0.5 * 0
=	60.38

Maxygen, Total Current Assets Related Terms

Thank you for viewing the detailed overview of Maxygen,'s Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Maxygen, (FRA:MYN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maxygen, Inc. (FRA:MYN) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Maxygen, Inc., is incorporated in Delaware. It is a biotechnology company. It discovers and develops improved next-generation protein pharmaceuticals for the treatment of disease and serious medical conditions. The Company's MAXY-G34 product candidate has been designed to be an improved next-generation pegylated, G-CSF for the treatment of chemotherapy-induced neutropenia. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The Company completed a Phase IIa clinical trial for its MAXY-G34 product candidate for the treatment of chemotherapy-induced neutropenia in breast cancer patients in which MAXY-G34 was safe and effective in reducing chemotherapy-induced neutropenia with no serious adverse events, drug-related grade 3 or 4 adverse events or immunogenicity reported in any patient receiving MAXY-G34. Adverse events were consistent with known side effects of G-CSF molecules. The Company is subject to regulation by the FDA and comparable regulatory agencies in foreign countries with respect to any development and commercialization of its MAXY-G34 product candidate or any other products it may acquire in the future.